Loading...
The desire to avoid long-term outpatient intravenous access complicates treatment of serious Staphylococcus aureus infections in persons who use drugs (PWUD). The lipoglycopeptide dalbavancin has activity against S. aureus and can be administered once weekly in the clinic setting.
Investigators at an academic center in Seattle retrospectively analyzed outcome data from 32 PWUD with S. aureus infections — predominantly bone and joint infections, bacteremia, and in 9 patients, endocarditis. Most patients (88%) were injection drug users and 47% were homeless. Methicillin-resistant S. aureus accounted for 88% of infections. After standard inpatient antibiotic therapy for an average of 13 days (including a first dose of dalbavancin), patients wer…